Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Reata, Comerica, and DZS and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Reata Pharmaceuticals Stock Plummets More Than 20%: Here's Why
Reata Pharmaceuticals Inc (NASDAQ: RETA) and its partner Kyowa Kirin Co Ltd have decided to discontinue  
Via Benzinga
Reata Pharma Tumbles After Scrapping Its Kidney Drug As Earnings Come In Mixed
Reata scrapped development of bardoxolone in chronic kidney disease. 
Via Investor's Business Daily
Recap: Reata Pharmaceuticals Q1 Earnings
Via Benzinga
Earnings Outlook For Reata Pharmaceuticals
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NASDAQ:RETA Investor Alert: Investigation over Possible Securities Laws Violations by Reata Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 06/07/2023 -- Reata Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 5/5
Via Investor Brand Network
Where Reata Pharmaceuticals Stands With Analysts
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Where Reata Pharmaceuticals Stands With Analysts
Via Benzinga
2 Top Healthcare Stocks Defying the Bear Market
These two healthcare stocks have been swimming against the current. 
Via The Motley Fool
Abercrombie & Fitch, Urban Outfitters, Photronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! 
Via InvestorPlace
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday. 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023
From Reata Pharmaceuticals, Inc.
Via Business Wire
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run. 
Via The Motley Fool
REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
From Kahn Swick & Foti, LLC
Via Business Wire
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The high-flyers have soared to new heights and further gains could be up ahead. 
Via The Motley Fool
The Stock That Tripled in a Day...And May Not Be Done
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios? 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.